Is Intuitive Surgical Stock A Pick After A 9% Fall In A Month Amid Mixed Q3?

ISRG: Intuitive Surgical logo
Intuitive Surgical

Intuitive Surgical (NASDAQ: ISRG) recently reported its Q3 results, with revenues lower but earnings beating our estimates. The company reported revenue of $1.7 billion, up 12% y-o-y and below our $1.8 billion estimate. Its adjusted earnings of $1.46 per share were up 23% y-o-y and above our estimated $1.42 per share. In this note, we discuss Intuitive Surgical’s stock performance, key takeaways from its recent results, and valuation.

ISRG stock has seen little change, moving slightly from levels of $275 in early January 2021 to around $265 now, vs. an increase of about 15% for the S&P 500 over this roughly 3-year period. Overall, the performance of ISRG stock with respect to the index has been lackluster. Returns for the stock were 32% in 2021, -26% in 2022, and 1% in 2023 (YTD). In comparison, returns for the S&P 500 have been 27% in 2021, -19% in 2022, and 10% in 2023 (YTD) – indicating that ISRG underperformed the S&P in 2022 and 2023.

In fact, consistently beating the S&P 500 – in good times and bad – has been difficult over recent years for individual stocks; for heavyweights in the Health Care sector, including LLY, UNH, and JNJ, and even for the mega-cap stars GOOG, TSLA, and MSFT. In contrast, the Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has outperformed the S&P 500 each year over the same period. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index, less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.

Relevant Articles
  1. Should You Pick Intuitive Surgical Stock At $370?
  2. Should You Pick Intuitive Surgical Stock At $375 After An Upbeat Q4?
  3. Procedure Volume Growth To Drive Intuitive Surgical’s Q3
  4. With 2x Potential Returns Is DexCom A Better Pick Over Intuitive Surgical?
  5. Here’s What To Expect From Intuitive Surgical’s Q2
  6. Should You Buy Intuitive Surgical Stock Over MDT?

Given the current uncertain macroeconomic environment with high oil prices and elevated interest rates, could ISRG face a similar situation as it did in 2022 and 2023 and underperform the S&P over the next 12 months – or will it see a strong jump? From a valuation perspective, ISRG stock looks attractive and will likely see higher levels over time. We estimate Intuitive Surgical’s Valuation to be $310 per share, reflecting a 16% upside from its current levels of $267. Our forecast is based on a 56x P/E multiple for ISRG and expected earnings of $5.55 on a per-share and adjusted basis for the full year 2023.

Intuitive Surgical’s revenue of $1.7 billion reflects a 12% y-o-y growth driven by a 19% rise in worldwide da Vinci procedure volume. The company placed 312 da Vinci systems during the quarter, reflecting a 2% y-o-y increase. A slowdown in bariatric procedures due to the increased adoption of glucagon-like peptide-1 (GLP-1) drugs and anti-corruption campaigns in China weighed on the overall system placements, a trend expected to continue in the near term. Its operating margin improved around 100 bps to 26.7% in Q3. This can be attributed to lower SG&A expenses as a percentage of revenue. Higher revenues and margin expansion led to a 23% y-o-y rise in the bottom line to $1.46 on a per-share and adjusted basis.

ISRG stock is trading at 14x sales, compared to the last five-year average of 21x. We believe investors will likely be better off picking ISRG on any dips for robust gains in the long run. However, the increased adoption of GLP-1 and the system placement slowdown in China remain key risk factors in realizing these gains.

Returns Oct 2023
MTD [1]
YTD [1]
Total [2]
 ISRG Return -9% 1% 279%
 S&P 500 Return -1% 10% 89%
 Trefis Reinforced Value Portfolio -2% 21% 520%

[1] Month-to-date and year-to-date as of 10/23/2023
[2] Cumulative total returns since the end of 2016

Invest with Trefis Market-Beating Portfolios
See all Trefis Price Estimates